Co-Diagnostics to Present Point-of-Care and At Home Testing Platform at Infectious Disease Diagnostics Virtual Conference

Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced that CEO Dwight Egan will present at the 2nd Annual MarketsandMarkets Infectious Disease Diagnostics and Point-Of-Care Testing Virtual Conference on March 11-12, 2021. Egan's presentation, scheduled for 12:10 pm ET on March 11, will cover the company's rapid PCR point-of-care and at-home testing platform for COVID-19 and other infectious diseases. This platform utilizes Co-Diagnostics' proprietary technology for enhanced testing efficiency. Attendees can register for the conference via the provided link.

SALT LAKE CITY, March 10, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will be presenting at the 2^nd Annual MarketsandMarkets Infectious Disease Diagnostics and Point-Of-Care Testing Virtual Conference, held March 11-12, 2021.

The Conference website states that the event will serve as a networking place for diagnostics professionals, industry specialists, and solution providers to address the rising innovation in point-of-care testing and the way it can be used as a disease prevention tool.

At 12:10 pm ET on March 11, Mr. Egan will deliver a presentation on Co-Diagnostics' new rapid PCR point-of-care and at home testing platform currently in development, and its potential use for COVID-19 testing at businesses, schools, homes, hotels, cruise ships, airports, airplanes and other locations, as well as its applications for other infectious diseases. The Company, whose COVID-19 tests have received widespread distribution around the world, created the new platform utilizing its proprietary CoPrimer™ technology and Direct Saliva extraction-free protocols. The device is being developed and engineered for Co-Diagnostics by internationally renowned experts in rapid PCR applications, and whose previous medical device inventions are in widespread use around the world.

Participants can register to attend at the Conference link posted above. Potential customers or distributors interested in being a part of the Company's ongoing strategy to increase distribution in Europe, Africa, and Asia can contact Co-Diagnostics at: info[at]codiagnostics.com.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Forward-Looking Statements:
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions.  Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company's liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company's products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company's balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances.  Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to rely on any forward-looking statements. Any forward-looking statement made by the Company in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

View original content to download multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-to-present-point-of-care-and-at-home-testing-platform-at-infectious-disease-diagnostics-virtual-conference-301244460.html

SOURCE Co-Diagnostics

FAQ

What will Co-Diagnostics present at the MarketsandMarkets conference?

Co-Diagnostics will present their rapid PCR point-of-care and at-home testing platform for COVID-19 and other infectious diseases.

When is Co-Diagnostics' presentation at the conference?

Dwight Egan's presentation is scheduled for 12:10 pm ET on March 11, 2021.

Where can I register for the MarketsandMarkets conference?

Participants can register for the conference using the link provided in the press release.

What technology does Co-Diagnostics' new testing platform use?

The platform utilizes Co-Diagnostics' proprietary CoPrimer technology and Direct Saliva extraction-free protocols.

What are the applications of Co-Diagnostics' testing platform?

The platform can be used for COVID-19 testing in various locations such as businesses, schools, homes, and airports, as well as for other infectious diseases.